SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
____________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: JULY 18, 2000
(Date of earliest event reported)
INCYTE GENOMICS, INC.
(FORMERLY INCYTE PHARMACEUTICALS, INC.)
(Exact name of registrant as specified in its charter)
DELAWARE 0-27488 94-3136539
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification
No.)
3160 PORTER DRIVE, PALO ALTO, CALIFORNIA 94304
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 855-0555
Item 5. Other Events.
-------------
Attached hereto as Exhibit 99.1 and incorporated by reference herein is the
press release dated July 18, 2000 announcing that Incyte's board of directors
have approved a two-for-one stock split in the form of a stock dividend. Incyte
stockholders of record at the close of business on August 7, 2000 will receive
one additional share for each share of common stock held at the time. The
additional shares will be distributed to eligible stockholders on August 31,
2000.
Item 7. Financial Statements and Exhibits.
------------------------------------
(c) Exhibits
99.1 Press release dated July 18, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: July 18, 2000
INCYTE GENOMICS, INC.
By /s/ John M. Vuko
-------------------
Name: John M. Vuko
Title: Executive Vice President and
Chief Financial Officer
EXHIBIT 99.1
- -------------
FOR IMMEDIATE RELEASE
- -----------------------
INCYTE
John Vuko
Chief Financial Officer
(650) 845-4106
INCYTE ANNOUNCES 2-FOR-1 STOCK SPLIT
PALO ALTO, CALIFORNIA, JULY 18, 2000 -- Incyte Genomics, Inc. (Nasdaq: INCY),
today announced that its board of directors has approved a two-for-one stock
split in the form of a stock dividend. Incyte stockholders of record at the
close of business on August 7, 2000 will receive one additional share for each
share of common stock held at that time. The additional shares will be
distributed to eligible stockholders on August 31, 2000. The stock split will
increase the number of shares of common stock outstanding from approximately 32
million to approximately 64 million.
Incyte Genomics, Inc. is the leading provider of an integrated platform of
genomic technologies designed to aid in the understanding of the molecular basis
of disease. Incyte develops and markets genomic databases and partnership
programs, genomic data management software, microarray-based gene expression
services, related reagents and services. These products, programs and services
assist pharmaceutical and biotechnology researchers with all phases of drug
discovery and development including gene discovery, understanding disease
pathways, identifying new disease targets and the discovery and correlation of
gene sequence variation to disease. For more information, visit Incyte's web
site at www.incyte.com.
Except for the historical information contained herein, the matters set forth in
this press release, are forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially. For a discussion of factors
that may cause results to differ, see Incyte's SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2000. Incyte
disclaims any intent or obligation to update these forward-looking statements.
###